Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.91 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.35 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | INPP5B | P32019 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.35 |
| ▸ | ITPR3 | Q14573 | 3/20 | 0.33 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.33 |
| ▸ | ITPR2 | Q14571 | 1/20 | 0.33 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL5083035 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL438388 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL3175481 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL17416228 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL16529918 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL19742227 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL16529917 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL9719940 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL597629 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL9799845 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081117-A1 | CONNECTED DRUG DELIVERY SYSTEM FOR ERYTHROPOIETIN STIMULATING AGENTS | Fresenius Medical Care Holdings, Inc. (US) | 2022-11-02 | — | — | EP | claimed |
| CN-114727783-A | Drug delivery system for the attachment of an erythropoietin stimulating agent | 费森尤斯医疗保健控股公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2021133440-A1 | CONNECTED DRUG DELIVERY SYSTEM FOR ERYTHROPOIETIN STIMULATING AGENTS | FRESENIUS MEDICAL CARE HOLDINGS, INC. (US) | 2021-07-01 | — | — | WO | claimed |
| US-20260041134-A1 | METHOD FOR PRODUCING NUTRITION-ADDED FOOD AND METHOD FOR PROVIDING NUTRITION-ADDED FOOD | NISSIN FOODS HOLDINGS CO., LTD. (JP) | 2026-02-12 | — | — | US | disclosed |
| EP-4505881-A1 | METHOD FOR PRODUCING NUTRIENT-ADDED FOOD AND METHOD FOR PROVIDING NUTRIENT-ADDED FOOD | NISSIN FOODS HOLDINGS CO., LTD. (JP) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023189062-A1 | METHOD FOR PRODUCING NUTRIENT-ADDED FOOD AND METHOD FOR PROVIDING NUTRIENT-ADDED FOOD | 日清食品ホールディングス株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-4081117-A1 | CONNECTED DRUG DELIVERY SYSTEM FOR ERYTHROPOIETIN STIMULATING AGENTS | Fresenius Medical Care Holdings, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-114727783-A | Drug delivery system for the attachment of an erythropoietin stimulating agent | 费森尤斯医疗保健控股公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021133440-A1 | CONNECTED DRUG DELIVERY SYSTEM FOR ERYTHROPOIETIN STIMULATING AGENTS | FRESENIUS MEDICAL CARE HOLDINGS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210187189-A1 | Connected Drug Delivery System for Erythropoietin Stimulating Agents | FRESENIUS MEDICAL CARE HOLDINGS, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20070213400-A1 | ALCOHOL-METABOLISM ENHANCING COMPOSITION AND INGESTA CONTAINING THE SAME | TAIYOKAGAKU CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1743634-A1 | ALCOHOL METABOLISM ACCELERATING COMPOSITION, AND FOOD OR DRINK CONTAINING THE COMPOSITION | Taiyokagaku Co., Ltd. (JP) | 2007-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041134-A1 | METHOD FOR PRODUCING NUTRITION-ADDED FOOD AND METHOD FOR PROVIDING NUTRITION-ADDED FOOD | SLC5A6, GC, NNT | FDPS 453/4885BLM 4100/4885TDP1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.